Century Therapeutics Incorporated is a biotech company developing transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also advancing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma. Century Therapeutics was founded in 2018 and is headquartered in Philadelphia, PA.
Name / Ticker | Price | Zen Rating |
---|---|---|
$21.94 | A | |
$5.52 | A | |
$2.78 | A |